ANI Pharma (ANIP) Tops Q1 EPS by 33c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/17/2024
- Stocks decline as interest rate uncertainty, earnings weigh
- ASML slides as Q1 sales fall short but firm still on track for 2025 revenue target
- US dollar weakens as market consolidates gains, but uptrend intact
- Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- Barnes & Noble Education (BNED) Enters Definitive Agreement with Immersion (IMMR)
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
ANI Pharmaceuticals Reports First Quarter 2021 Results
May 7, 2021 6:50 AM EDT-- First quarter 2021 net revenues of $54.5 million; net income of $0.1 million and diluted earnings per share of $0.01 --
-- First quarter adjusted non-GAAP EBITDA of $18.9 million and adjusted non-GAAP diluted earnings per share of $1.04 --
-- Cortrophin® Gel sNDA re-filing on track for Q2 2021 submission --
-- Strengthened R&D engine and enhanced generics and CDMO business through pending acquisition of Novitium Pharma--
-- Expanded branded products portfolio through April 1 acquisition of Sandoz Inc. NDAs --
... More
